Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (91-100 of 301) with videos related to

Pageof 31
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
The New England Journal of Medicine|December 26, 2003
Single versus double autologous stem-cell transplantation for multiple myelomaMichel Attal, Jean-Luc Harousseau, Thierry Facon, et al.
European Journal of Haematology|December 1, 2011
Prognostic value of PINI index in patients with multiple myelomaSophie Dupire, Mathieu Wemeau, Houria Debarri, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Scientific Reports|August 25, 2017
Logic programming reveals alteration of key transcription factors in multiple myelomaBertrand Miannay, Stéphane Minvielle, Olivier Roux, et al.
Blood|March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
International Journal of Hematology|March 27, 2026
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trialKenshi Suzuki, Morio Matsumoto, Hiroyuki Takamatsu, et al.
Haematologica|July 1, 2026
<i>Erratum</i> to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial"Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Leukemia & Lymphoma|November 1, 2017
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapyEmmanuelle Le Ray, Lisa Belin, Corine Plancher, et al.
Pageof 31

Showing results (91-100 of 301) with videos related to

Sort By:
Pageof 31
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
The New England Journal of Medicine|December 26, 2003
Single versus double autologous stem-cell transplantation for multiple myelomaMichel Attal, Jean-Luc Harousseau, Thierry Facon, et al.
European Journal of Haematology|December 1, 2011
Prognostic value of PINI index in patients with multiple myelomaSophie Dupire, Mathieu Wemeau, Houria Debarri, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Scientific Reports|August 25, 2017
Logic programming reveals alteration of key transcription factors in multiple myelomaBertrand Miannay, Stéphane Minvielle, Olivier Roux, et al.
Blood|March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
International Journal of Hematology|March 27, 2026
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trialKenshi Suzuki, Morio Matsumoto, Hiroyuki Takamatsu, et al.
Haematologica|July 1, 2026
<i>Erratum</i> to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial"Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Leukemia & Lymphoma|November 1, 2017
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapyEmmanuelle Le Ray, Lisa Belin, Corine Plancher, et al.
Pageof 31